Prolira
Prolira is developing a medical device to diagnose delirium with a three-point EEG measurement.
Introduction
In portfolio since August 2023
Healthcare
Venture & Growth
Add ons
- Praktische GGZ
- ad Astra
- …
About Prolira
Prolira originated as a spin-off from Utrecht University Medical Centre (NL), now an international and privately owned healthcare scale-up company.
Delirium is common in hospitalized patients with often serious consequences. Active use of patient brain state information is essential for making better informed medical decisions
achieving improved patient care with better outcomes. Prolira provides the world’s first objective brain monitor (DeltaScan®) to hospitals, as well as data-driven support that quantifies the positive impact of DeltaScan implementation in patient care protocols.
Why are we investing in Prolira?
In the coming years, routine monitoring of brain status will become part of the normal set of vital parameters. Our goal is to further strengthen our position by supporting hospital departments to achieve improved care for their patients with acute brain failure.
“This growth capital investment enables greater acceptance of our offering in key European countries and, following FDA approval, also a launch in the US,” confirms Rutger van Merker, founder of Prolira.
Holland Capital, together with investors Borski Fund, ROM Regio Utrecht, Health Innovations and Oost NL, is investing €5 million in Prolira BV.
Add on
“Holland Capital offered the best strategic support in addition to a solid financial foundation. We had a good feeling about that”
Technology portfolio
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Inselstraße 34
40479 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.de